Cybele Official Message
Type 2 Diabetes Mellitus Can be reversed over time with Consistency and Medication.
The 4-Pillar Reverse Program
What it Was Designed to Do
Address long-term metabolic dysfunction in Type 2 Diabetes — not just blood sugar numbers.
Standard diabetes treatment focuses on lowering blood glucose. Over time, however, Type 2 Diabetes progresses due to underlying metabolic dysfunction — including insulin resistance, lipid imbalance, chronic inflammation, and organ stress.
The 4-Pillar Program was designed to work alongside prescribed medication to address these deeper metabolic processes.
Pharmacological Control
Metformin and Sulfonylureas
Metabolic Support
Cogent DB+
Physiological Activation
15 minutes of daily movement
Nutritional Control
Reduces glycemic volatility
Without addressing metabolic dysfunction, blood sugar control alone does not stop disease progression.
The 4-Pillar Program exists to close this gap.
Human Clinical Evidence
Across multiple human clinical studies, COGENT DB demonstrated a consistent ability to improve the metabolic environment underlying Type 2 Diabetes — not merely reduce glucose values.
These findings suggest a metabolic intervention capable of addressing a limitation modern diabetes medications were never designed to solve.
Observed between 1998–2002 across India, Malaysia & Sudan on the same formulation — COGENT DB / COGENT DB+Fasting Blood Glucose
Post-Prandial Glucose
HbA1c Levels
Across all studies, COGENT DB demonstrated significant, reproducible metabolic improvement in real human bodies:
- Sustained improvement in glucose parameters (FBG, PPBG, HbA1c) beyond what oral hypoglycemics achieved alone.
- Significant reduction in other metabolic markers (lipids, urinary proteins) indicating improved overall metabolic health.
- No clinically significant liver or kidney toxicity, even alongside routine allopathic drugs.
Routine side effects of prescribed diabetes medications (fatigue, bloating, frequent urination) were notably reduced. COGENT DB provided metabolic support while mitigating common drug-related symptoms.
Why Cogent DB+ Works When Medication Alone Does Not
Clinical change observed over 3 months
(Human trials – alongside prescribed diabetes medication)
Control Group Vs Treatment Group
| Parameters | Control (Day 0 → 3 Month) | Treatment (Day 0 → 3 Month) | Treatment Change (%) |
|---|---|---|---|
| Fasting Blood Glucose | 10.5 → 12.2 | 12.2 → 8.8 | 27.9% |
| Post-Prandial Glucose (PPG (2.00)) | 15.0 → 18.3 | 18.2 → 11.9 | 34.6% |
| HbA1c | 9.5 → 10.4 | 11.2 → 8.9 | 20.5% |
| Total Glycated Hemoglobin (%) | 11.2 → 12.4 | 11.2 → 9.5 | 13.0% |
| Liver Stress Markers | |||
| AST (Aspartate Aminotransferase) | 26.3 → 40.3 | 36.8 → 32.4 | 7.0% |
| Total Bilirubin | 13.1 → 15.1 | 13.1 → 11.6 | 10.6% |
| Stimulated Insulin | 25.4 → 34.3 | 52.0 → 38.9 | 25.2% |
| Fasting C-Peptide | 1.32 → 1.89 | 1.78 → 1.50 | 15.7% |
* Data observed from Day 0 to 3 months of human observation (Malaysia, Type-2 diabetic, patients, adjunct to prescribed care).